Investigational drug · Phase 3
NNC0487-0111
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Obstructive Sleep Apnoea.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
10 still active
All registered trials
23
Any phase or sponsor naming "NNC0487-0111"
First trial start
2023
Sep 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNC0487-0111", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Obstructive Sleep Apnoea
- Diabetes Mellitus
- Knee Osteoarthritis (OA)
- Heart Failure
- Diabetes Mellitus, Type 2
- Osteoarthritis, Knee
- Type 2 Diabetes (T2D)
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Heart failure · Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NNC0487-0111" as an intervention, largest first.
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07567001 · 5,610 participants (planned) · Start May 11, 2026 · Primary completion Jul 23, 2029
Drug: NNC0487-0111; Placebo · For: Obesity; Heart Failure
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 838 sites in all
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07339423 · 1,150 participants (planned) · Start Feb 24, 2026 · Primary completion Jun 26, 2029
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity
Sites: Miramar, Florida; Orlando, Florida; Conyers, Georgia · 72 sites in all
- AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07400107 · 985 participants · Start May 20, 2026 · Primary completion Dec 19, 2028
Drug: NNC0487-0111; Semaglutide and 2 more · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Hollywood, Florida; Orange City, Florida; Weston, Florida · 122 sites in all
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07533175 · 638 participants (planned) · Start Apr 13, 2026 · Primary completion Aug 7, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Diabetes Mellitus; Overweight; Obesity
Sites: Birmingham, Alabama; Escondido, California; Lomita, California · 73 sites in all
- AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07503210 · 606 participants · Start Apr 21, 2026 · Primary completion Jun 6, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity
Sites: Anniston, Alabama; Walnut Creek, California; Orlando, Florida · 72 sites in all
- A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06542874 · 448 participants · Start Aug 7, 2024 · Primary completion Oct 1, 2025
Drug: NNC0487-0111 subcutanous; Placebo (NNC0487-0111 subcutanous) and 2 more · For: Type 2 Diabetes (T2D)
Sites: Birmingham, Alabama; Los Angeles, California; Santa Ana, California · 137 sites in all
- A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07481630 · 400 participants (planned) · Start Apr 13, 2026 · Primary completion Aug 14, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111 ) · For: Obesity; Knee Osteoarthritis (OA)
Sites: Phoenix, Arizona; Walnut Creek, California; Hamden, Connecticut · 82 sites in all
- AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07822061 · 400 participants (planned) · Start Sep 7, 2026 · Primary completion Feb 5, 2029
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Overweight; Obesity
Sites: Sapporo, Japan; Yamato-shi, Japan; Chigasaki-shi, Japan · 26 sites in all
- AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07509307 · 400 participants (planned) · Start Apr 20, 2026 · Primary completion Aug 14, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity; Overweight; Osteoarthritis, Knee
Sites: Escondido, California; Lancaster, California; Palm Springs, California · 81 sites in all
- AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07571109 · 300 participants (planned) · Start May 5, 2026 · Primary completion Jun 26, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity; Overweight; Obstructive Sleep Apnoea
Sites: Gilbert, Arizona; Bradenton, Florida; Naples, Florida · 92 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Panou T, Gouveri E, Popovic DS, et al. · Diabetes Ther 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.